Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ: CORT) has announced results from its DAZALS Phase 2 trial evaluating dazucorilant in ALS patients. The study tested two doses (150mg and 300mg) of the selective cortisol modulator but did not meet its primary endpoint measuring change in ALS Functional Rating Scale-Revised (ALSFRS-R). While patients experienced increased gastrointestinal upset with dazucorilant, notably, no deaths occurred in the 300mg treatment group (0/83) compared to 5 deaths in the placebo group (5/82), showing statistical significance (p=0.02). The drug has received Fast Track Designation from the FDA. An open-label extension study continues, with overall survival assessment planned for March 2025.
Corcept Therapeutics (NASDAQ: CORT) reported strong Q3 2024 financial results with revenue of $182.5 million, up 48% year-over-year. Net income reached $47.2 million with EPS of $0.41. The company increased its 2024 revenue guidance to $675-700 million and reported cash and investments of $547.6 million.
The company announced positive results from its Phase 3 GRADIENT trial in Cushing's syndrome patients, supporting findings from the pivotal GRACE study. Patients treated with relacorilant showed meaningful improvements in various symptoms. Corcept plans to submit a new drug application (NDA) for relacorilant this quarter.
Corcept Therapeutics (NASDAQ: CORT) has announced it will release its third quarter financial results and provide a corporate update on October 30, 2024. The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day. Participants must pre-register to receive dial-in details and a unique access PIN. A listen-only webcast option will also be available, with a replay accessible through the company's website.
Corcept Therapeutics (NASDAQ: CORT) reported strong Q2 2024 financial results, with revenue of $163.8 million, a 39% increase year-over-year. The company raised its 2024 revenue guidance to $640 – $670 million. Net income per share was $0.32, up from $0.25 in Q2 2023. Cash and investments stood at $492.5 million.
Corcept's clinical development pipeline showed progress, with positive results from the GRACE trial for relacorilant in Cushing's syndrome. The company plans to submit a New Drug Application for relacorilant in Q4. The CATALYST study revealed a 24% prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Results from several late-stage trials, including ROSELLA for ovarian cancer and DAZALS for ALS, are expected by year-end.
Corcept Therapeutics (NASDAQ: CORT) has announced it will release its second quarter financial results and provide a corporate update on July 29, 2024. The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day. Participants must register in advance to receive a dial-in number and unique access PIN. A listen-only webcast will also be available. A replay of the call will be accessible on the Investors / Events section of Corcept.com.
Corcept Therapeutics announced results from the prevalence phase of their CATALYST clinical trial at the American Diabetes Association’s 84th Scientific Sessions.
The trial enrolled 1,055 patients with difficult-to-control type 2 diabetes across 36 U.S. sites, making it the largest study of its kind. The results showed a 24% prevalence rate of hypercortisolism among these patients, a higher figure than previously assumed.
Hypercortisolism was notably common in patients with cardiovascular issues and those needing multiple medications for diabetes and hypertension control.
This new data may lead to better diagnosis and treatment strategies for hypercortisolism, a serious condition often overlooked in type 2 diabetes management.
Details of the treatment phase, where eligible patients received either Korlym or a placebo, are expected by year-end.
Corcept Therapeutics (NASDAQ: CORT) announced that results from the Phase 3 GRACE trial of relacorilant, a selective cortisol modulator for treating hypercortisolism (Cushing’s syndrome), will be presented at two major conferences in June 2024. The presentations will take place at the Endocrine Society (ENDO) annual meeting in Boston on June 3, and at the Heart in Diabetes (HiD) conference in Philadelphia on June 7. Key findings will be shared by Dr. Rosario Pivonello and Dr. Ralph DeFronzo, highlighting the impact of relacorilant on hypertension and hyperglycemia. Detailed results will be accessible on Corcept’s website post-events.
Corcept Therapeutics (NASDAQ: CORT) announced positive results from its Phase 3 GRACE trial of relacorilant for treating hypercortisolism (Cushing’s syndrome). The trial met its primary endpoint, showing significant improvements in hypertension, hyperglycemia, and other symptoms. In the randomized withdrawal phase, patients receiving relacorilant had a notably lower loss of blood pressure control compared to those on placebo (odds ratio: 0.17; p-value: 0.02). The drug was well-tolerated, with no significant safety differences observed. Corcept plans to submit a New Drug Application in Q3, with additional data presentations scheduled for June.
Corcept Therapeutics Incorporated reported strong financial results for the first quarter of 2024, with a revenue of $146.8 million, a 39% increase from the same period in 2023. The company raised its 2024 revenue guidance to $620 - $650 million and reported a net income per common share of $0.25. Corcept continues to focus on developing medications for various disorders by modulating the effects of cortisol. The company highlighted record numbers of new prescribers and patients for its drug Korlym in the first quarter, showcasing its growing presence in the market.
Corcept Therapeutics Incorporated has completed enrollment in the Phase 4 CATALYST trial, the largest study ever conducted to establish the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Approximately 25% of the over 1,000 patients enrolled were identified as having hypercortisolism, a higher rate than previously assumed. Final prevalence data will be shared at the American Diabetes Association’s 84th Scientific Sessions in June, with treatment data expected by year-end. The findings from CATALYST aim to improve the identification and treatment of patients with hypercortisolism.